Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation
- PMID: 26187356
- DOI: 10.1016/j.vph.2015.07.005
Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors exert a potent anti-hyperglycemic effect and reduce cardiovascular risk in type 2 diabetic patients. Several studies have shown that DPP-4 inhibitors including sitagliptin have beneficial effects in atherosclerosis and cardiac infarction involving reactive oxygen species. Here, we show that gemigliptin can directly attenuate the abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) via enhanced NF-E2-related factor 2 (Nrf2) activity. Gemigliptin dramatically prevented ligation injury-induced neointimal hyperplasia in mouse carotid arteries. Likewise, the proliferation of primary VSMCs was significantly attenuated by gemigliptin in a dose-dependent manner consistent with a decrease in phospho-Rb, resulting in G1 cell cycle arrest. We found that gemigliptin enhanced Nrf2 activity not only by mRNA expression, but also by increasing Keap1 proteosomal degradation by p62, leading to the induction of Nrf2 target genes such as HO-1 and NQO1. The anti-proliferative role of gemigliptin disappeared with DPP-4 siRNA knockdown, indicating that the endogenous DPP-4 in VSMCs contributed to the effect of gemigliptin. In addition, gemigliptin diminished TNF-α-mediated cell adhesion molecules such as MCP-1 and VCAM-1 and reduced MMP2 activity in VSMCs. Taken together, our data indicate that gemigliptin exerts a preventative effect on the proliferation and migration of VSMCs via Nrf2.
Keywords: Anti-oxidative stress; Cardiovascular diseases; Carotid artery; Cell cycle; Gemigliptin (PubChem CID: 11953153); Reactive oxygen species; p62–Keap1–Nrf2 pathway.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Redox-sensitive transcription factor Nrf2 regulates vascular smooth muscle cell migration and neointimal hyperplasia.Arterioscler Thromb Vasc Biol. 2013 Apr;33(4):760-8. doi: 10.1161/ATVBAHA.112.300614. Epub 2013 Feb 14. Arterioscler Thromb Vasc Biol. 2013. PMID: 23413426
-
The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms.Mol Cell Endocrinol. 2015 Apr 15;405:25-34. doi: 10.1016/j.mce.2015.01.025. Epub 2015 Feb 4. Mol Cell Endocrinol. 2015. PMID: 25661535
-
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.Eur J Pharmacol. 2016 Oct 5;788:54-64. doi: 10.1016/j.ejphar.2016.06.016. Epub 2016 Jun 11. Eur J Pharmacol. 2016. PMID: 27298192
-
Matrix Metalloproteinase 2 as a Potential Mediator of Vascular Smooth Muscle Cell Migration and Chronic Vascular Remodeling in Hypertension.J Vasc Res. 2015;52(4):221-31. doi: 10.1159/000441621. Epub 2016 Jan 6. J Vasc Res. 2015. PMID: 26731549 Review.
-
DPP-4 inhibition: А novel therapeutic approach to the treatment of pulmonary hypertension?Pharmacol Ther. 2019 Sep;201:1-7. doi: 10.1016/j.pharmthera.2019.05.007. Epub 2019 May 13. Pharmacol Ther. 2019. PMID: 31095977 Review.
Cited by
-
Gemigliptin Inhibits Interleukin-1β-Induced Endothelial-Mesenchymal Transition via Canonical-Bone Morphogenetic Protein Pathway.Endocrinol Metab (Seoul). 2020 Jun;35(2):384-395. doi: 10.3803/EnM.2020.35.2.384. Epub 2020 Jun 24. Endocrinol Metab (Seoul). 2020. PMID: 32615723 Free PMC article.
-
Association of Circulating Heme Oxygenase-1, Lipid Profile and Coronary Disease Phenotype in Patients with Chronic Coronary Syndrome.Antioxidants (Basel). 2021 Dec 15;10(12):2002. doi: 10.3390/antiox10122002. Antioxidants (Basel). 2021. PMID: 34943105 Free PMC article.
-
The Role of Oxidative Stress and Antioxidants in Diabetic Wound Healing.Oxid Med Cell Longev. 2021 Feb 4;2021:8852759. doi: 10.1155/2021/8852759. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 33628388 Free PMC article. Review.
-
DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.Front Immunol. 2019 May 9;10:1050. doi: 10.3389/fimmu.2019.01050. eCollection 2019. Front Immunol. 2019. PMID: 31134095 Free PMC article. Review.
-
Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity.PLoS One. 2017 Mar 23;12(3):e0174295. doi: 10.1371/journal.pone.0174295. eCollection 2017. PLoS One. 2017. PMID: 28334048 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous